Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a biotechnology company dedicated to the development of novel therapies for severe, rare muscle disorders. Headquartered in Boulder, Colorado, the company is renowned for its innovative approach to treating diseases involving skeletal muscle. Founded with Series A financing from OrbiMed, Edgewise Therapeutics is focused on the discovery, development, and commercialization of orally bioavailable, small molecule therapies designed to address musculoskeletal diseases.
The core mission of Edgewise Therapeutics is to transform the lives of patients suffering from debilitating muscle conditions. The company’s clinical-stage biopharmaceutical expertise is reflected in its robust pipeline of potential treatments, which aim to offer improved patient outcomes and enhanced quality of life.
Among its current projects, Edgewise Therapeutics is working on several promising candidates that target specific muscle-related conditions. By leveraging advanced research methodologies and cutting-edge technology, the company is able to create therapies that are not only effective but also accessible to a broader patient population.
Financially, Edgewise Therapeutics is well-positioned with strong backing from investors and strategic partners. The company continues to achieve significant milestones in its development programs, further solidifying its reputation as a leader in the biopharmaceutical landscape.
In recent news, Edgewise Therapeutics has made noteworthy progress with its clinical trials and has expanded its research partnerships to expedite the development of its drug candidates. The latest developments underline the company's commitment to innovation and excellence in the field of muscle disease therapeutics.
- Location: Boulder, Colorado
- Core Focus: Novel therapies for rare muscle disorders
- Key Projects: Orally bioavailable small molecule therapies
- Partnerships: Supported by OrbiMed and other strategic investors
Edgewise Therapeutics (NASDAQ: EWTX) announced FDA authorization for the LYNX Phase 2 clinical trial of EDG-5506 in children with Duchenne Muscular Dystrophy (DMD). The trial aims to enroll approximately 27 participants, aged 4 to 9, across the U.S. to assess safety and efficacy over 12 weeks. EDG-5506, previously successful in BMD trials, is designed to mitigate muscle damage. Positive feedback from patient advocacy groups underscores the significance of expanding treatment options for DMD patients, a condition affecting 12,000-15,000 in the U.S.
Edgewise Therapeutics announced positive interim results for its EDG-5506 treatment in Becker muscular dystrophy (BMD) from the ARCH study. The ongoing trial indicates a significant reduction in muscle damage biomarkers, with creatine kinase and troponin I decreasing by 30% and 68%, respectively, after two months. The company has initiated Phase 2 trials for both BMD and plans for Duchenne muscular dystrophy (DMD) later in 2022. Financially, as of June 30, 2022, Edgewise reported
Edgewise Therapeutics (NASDAQ: EWTX) has announced that its senior management will participate in the virtual 2022 Wedbush PacGrow Healthcare Conference on August 9-10. The company is focused on developing therapies for rare muscle disorders. A live panel discussion titled “Muscle Beach” is scheduled for August 9 at 2:20 pm ET and will be available for replay. Edgewise employs a unique drug discovery platform aimed at treating severe neuromuscular and cardiac disorders.
Edgewise Therapeutics, Inc. (EWTX) has initiated the CANYON Phase 2 clinical trial for EDG-5506, targeting Becker Muscular Dystrophy (BMD). This trial will observe 66 individuals over 12 months to assess safety, pharmacokinetics, biomarkers, and functional measures. There are no approved treatments for BMD, highlighting the unmet medical need. EDG-5506 is designed to protect muscle fibers in dystrophinopathies like BMD and Duchenne muscular dystrophy, following positive Phase 1 results. This trial marks a critical step in potential therapy development for individuals with BMD.
Edgewise Therapeutics announced positive interim results from the ARCH study, evaluating EDG-5506 for Becker Muscular Dystrophy (BMD). After two months of treatment, key muscle damage biomarkers creatine kinase and fast skeletal muscle troponin I decreased by 30% and 68%, respectively. BMD patients showed increased physical activity compared to earlier study levels. EDG-5506 was well-tolerated; patients escalated to 15 mg daily without serious adverse effects. A conference call is scheduled for June 21 to discuss these findings further.
Edgewise Therapeutics (NASDAQ: EWTX) is set to present new interim data from the ARCH study on EDG-5506, targeting Becker Muscular Dystrophy (BMD), at the 2022 New Directions Conference from June 20-23, 2022. A conference call discussing this data will occur on June 21 at 9 a.m. ET. Additionally, further presentations will be showcased at the 2022 PPMD Annual Conference on June 23-26. EDG-5506 has received Fast Track designation from the FDA, emphasizing its potential in treating severe neuromuscular disorders.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced that its senior management will participate in two upcoming investor conferences:
- Jefferies Healthcare Conference: Presentation on June 10, 2022, at 10 am ET.
- Goldman Sachs Annual Global Healthcare Conference: Fireside chat on June 15, 2022, at 4 pm PT (7 pm ET).
Both events will be webcast live and available for replay. Edgewise focuses on developing therapies for rare muscle disorders using a proprietary drug discovery platform.
Edgewise Therapeutics (EWTX) announced significant progress, having completed enrollment in the ARCH study for EDG-5506 targeting Becker muscular dystrophy (BMD). A Natural History Trial for BMD has commenced, aiming to recruit around 150 participants. The company reported a net loss of $14.7 million or $0.30 per share for Q1 2022, with cash reserves of $265.8 million expected to sustain operations through 2024. Phase 2 trials for BMD and Duchenne muscular dystrophy (DMD) are planned for 2022, with interim data from the ARCH study anticipated in Q2 2022.
Edgewise Therapeutics (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference fireside chat is scheduled for May 10, 2022, at 8:40 am PT. The RBC Capital Markets Global Healthcare Conference fireside chat will occur on May 18, 2022, at 3:35 pm ET. Presentations will be webcast live and available for replay on Edgewise’s events page.
Edgewise Therapeutics (NASDAQ: EWTX) has launched a funded observational trial to study Becker Muscular Dystrophy (BMD) progression. Led by the GRASP consortium and Virginia Commonwealth University, the two-year study aims to recruit around 150 participants aged 8 and older across the U.S. and Europe. The trial will collect data to enhance understanding of BMD, which currently has no approved therapies in the U.S. Edgewise's lead candidate, EDG-5506, has received Fast Track designation and is anticipated to enter Phase 2 trials for BMD in 2022.
FAQ
What is the current stock price of Edgewise Therapeutics (EWTX)?
What is the market cap of Edgewise Therapeutics (EWTX)?
What is Edgewise Therapeutics, Inc.?
Where is Edgewise Therapeutics located?
What is the core focus of Edgewise Therapeutics?
What are Edgewise Therapeutics' key projects?
Who financed Edgewise Therapeutics' Series A round?
Is Edgewise Therapeutics a public company?
What recent achievements has Edgewise Therapeutics made?
What kind of diseases is Edgewise Therapeutics targeting?
What type of therapies is Edgewise Therapeutics developing?
What makes Edgewise Therapeutics' treatments innovative?
